Results 111 to 120 of about 16,485 (256)

Cancer incidence and novel therapies developed in Japan

Journal of Stem Cells and Regenerative Medicine, 2012
According to the ministry of Health, Labour and welfare of Japan, Cancer has been the leading cause of death in Japan since 1981. [1] As per the data in 2010, in Japan, one in every three deaths was due to cancer.
Masaru Iwasaki
doaj  

Lymphokine-activated killer cell induction in tumor-infiltrating leukocytes from colon cancer patients [PDF]

, 1989
Edgar D. Staren, Steven G. Economou, Jules E. Harris, Donald P. Braun   +3 more
openalex   +1 more source

Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes [PDF]

, 1990
Although the relative contribution of different immune effector functions to clearing tissues of cytomegalovirus is controversial, the contribution of CD8+ T lymphocytes has generally been accepted as essential. In this report, we show that under certain
Jonjic, Stipan, Koszinowski, Ulrich H., Lucin, Pero, Pavic, Ivica, Rukavina, Daniel   +4 more
core  

An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides

Drug Design, Development and Therapy, 2014
Jiang Cheng,1,2 Zhi-Wei Zhou,2 Hui-Ping Sheng,3 Lan-Jie He,4 Xue-Wen Fan,1 Zhi-Xu He,5 Tao Sun,6 Xueji Zhang,7 Ruan Jin Zhao,8 Ling Gu,9 Chuanhai Cao,2 Shu-Feng Zhou2,5 1Department of Neurology, General Hospital of Ningxia Medical University, Yinchuan ...
Cheng J, Zhou ZW, Sheng HP, He LJ, Fan XW, He ZX, Sun T, Zhang X, Zhao RJ, Gu L, Cao CH, Zhou SF   +11 more
doaj  

Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2.

, 1988
Salem Chouaı̈b, Jacques Bertoglio, Jean‐Yves Blay, Carmen Marchiol, D Fradelizi   +4 more
openalex   +1 more source

Hurdles overcome in technology transfer for AIET and Positive outcome in Indian patients

Journal of Stem Cells and Regenerative Medicine, 2012
Introduction Cell based immunotherapies have been in practice in Japan for the past two decades with established clinical trials on its efficacy in both solid tumours and hematological malignancies including gastric cancer, ovarian cancer , lung cancer ...
Dedeepiya V, Ramanan G,, Munirathnam D, Sumana P, Terunuma H, Senthilkumar R, Srinivasan T, Reena H, Preethy S, Abraham S   +9 more
doaj  

Triggering of the cytotoxic activity of murine natural killer and lymphokine-activated killer cells through the NK2.1 antigen. [PDF]

, 1993
Lidia Morelli, Suzanne Lemieux
openalex   +1 more source

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells. [PDF]

Oncol Rep, 2023
Kimura K, Kuwahara A, Suzuki S, Nakanishi T, Kumagai I, Asano R.   +5 more
europepmc   +1 more source

The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and В16 melanoma resistant to doxorubicin [PDF]

, 2008
Aim: To study the influence of doxorubicin at low doses on antitumor action of activated (LAK) and non-activated lymphocytes from lymph nodes toward tumor cells of mice bearing doxorubicin-resistant and doxorubicin-sensitive transplantable MC ...
Belova, O.B., Berezhnaya, N.M., Vinnichuk, Yu.D.   +2 more
core  

T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma. [PDF]

Oncotarget, 2018
Quan C, Xiao J, Duan Q, Yuan P, Xue P, Lu H, Yan M, Guo D, Xu S, Zhang X, Lin X, Wang Y, Dogan S, Zhang J, Zhu F, Ke C, Liu L.   +16 more
europepmc   +1 more source